Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2020-03-04 Audit Report / Informat…
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from the company Pangen. It provides a summary of the audit opinion (unqualified/proper), key financial data, and auditor information. According to the 'Menu vs Meal' rule, this is a short announcement summarizing the audit results rather than the full, multi-page audit report itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2019
2020-03-04 Korean
기타경영사항(특허권취득)(자율공시)(Antibody to be cross-linked to human and mouse Sema 3A, and use thereof)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from Pangen regarding the acquisition of a patent for an antibody treatment. It is categorized as a 'voluntary disclosure' (자율공시) in the Korean regulatory context. Since it does not fit into specific categories like financial reports, M&A, or share transactions, it falls under the general regulatory filing category.
2020-02-14 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) by the company Pangen. It details the contract value, counterparty, and terms. Since this is a specific regulatory disclosure regarding a business contract that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2020-02-12 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Pangen. It outlines the date, time, location, and the agenda items (such as approval of financial statements, election of directors, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting items, which falls under the Proxy Solicitation & Information Statement category.
2020-02-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Pangen) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (often referred to as a 'Fair Disclosure' or 'Material Event' filing) that provides preliminary financial results before the final audit. Since it is an initial announcement of financial performance metrics rather than a full annual report or a simple report publication notice, it falls under the Earnings Release (ER) category.
2020-01-22 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a formal regulatory announcement regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) by the company Pangen. It details the contract value, counterparty, and duration. Since this is a specific regulatory disclosure of a material business event that does not fit into the other specialized categories like M&A or financial reports, it is classified as a general regulatory filing.
2020-01-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.